Johnson & Johnson: Positioning for Market Leadership?

Date: July 22, 2009
Price:
US$ 295.00
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: J9DBABA7B67EN
Leaflet:

Download PDF Leaflet

Johnson & Johnson: Positioning for Market Leadership?
How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues?

For competitors and investors alike this is a key question, and one that must be considered in the light of two recent and significant developments.

The acquisition by Johnson & Johnson of Cougar Biotechnology for almost US$1 billion in May 2009 spearheads a move by the company to become a top 5 player in the fast-growing oncology sector - a therapy area relatively new to J&J.

An audacious move to secure the non-US distribution rights to Remicade and Simponi from Schering-Plough; a move triggered by the proposed merger of Schering-Plough with Merck & Co. If successful, this would add significant revenues to J&J's coffers at a stroke.

The focus on novel oncology product development is timely. Although J&J can boast 9 blockbusters in its product line-up, it is feeling the pressure of generic competition on Risperdal and Topamax; a situation that will not be improved by the loss of patent protection for Levaquin and Remicade in the medium term.

Easily assess J&J’s strategy!

For a complete and concise assessment of J&J’s strategic thinking and development, turn to this new Firstword report Johnson & Johnson: Pharma Growth Strategy. Using primary source data and information, this 25-page report presents a timely, comprehensive yet easy-to-read briefing for all executives tracking developments at one of the industry’s major players.
This sharply-focussed, cost-effective report will tell you:
  • the current product range and sales performance;
  • J&J’s strategic plan and how is it being deployed;
  • the focus of J&J’s research pipeline and the ambition for oncology market leadership;
  • the strategic thinking underpinning development in key emerging markets, such as India and China;
  • the implications of the Merck & Co/Schering-Plough merger for J&J; and
  • expected product filings in key markets around the world.
EXECUTIVE SUMMARY

CURRENT SITUATION - A SUMMARY

J&J - Key Pharmaceutical Revenues, 2007-2009

STRATEGY

Key Elements of the Strategy
An Evolving Portfolio
NME Approvals/Filings, 2007-2013
NME Approvals/Filings, 2008 – date
Major Line Extensions, 2008 – date
Robust Pipeline
Planned NME Filings, 2009 – 2013
Potential Line Extensions by 2013
Potential in Emerging Markets
Potential Filings in India, China and Japan, 2009-2013
"Pipeline in a Product"

PHARMA R&D STRATEGY

Focus on Oncology
Oncology Highlights
Velcade
Doxil
Yondelis
Tumour Microenvironment Disrupting Agents
Biomarkers and Diagnostics
Tianjin Medical
University Cancer Institute and Hospital
Cougar Biotechnology
Cougar Biotechnology Acquisition
Cougar Portfolio
Recent Clinical Trial Results

MERCK/SCHERING-PLOUGH MERGER

Significance to Johnson & Johnson
Remicade
Simponi
Issues over Simponi
Acquisition of Elan's Alzheimer's immunotherapy (AI) programme
Reference Table - Late-Stage R&D Pipeline, April 2009

INDEX

RECENT ARTICLES
Skip to top


Ask Your Question

Johnson & Johnson: Positioning for Market Leadership?
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: